Women shouldn't have to choose hysterectomy to protect their health. Early detection is key.
AOA Dx
Biotechnology Research
Denver, CO 6,848 followers
Revolutionizing early diagnosis of Ovarian Cancer
About us
AOA Dx is developing the next frontier in early-stage cancer detection for women through its pioneering work in glycolipids and proprietary biomarker technology. Our revolutionary tumor marker ganglioside platform, GlycoLocate™, is paving the way for life-saving early cancer detection. In a first of its kind, AOA Dx is developing AKRIVIS GD™, an early-stage liquid biopsy test for ovarian cancer, that has proven excellent sensitivity and specificity in a recent study. We foresee novel tumor biomarker gangliosides as the future for diagnosis, prognosis, monitoring, and eventually targeted therapies across multiple cancers. AOA Dx was co-founded by three experts and passionate advocates of women’s health, who have worked together at two previous diagnostic startups, that both resulted in successful exits upon commercialization. AOA Dx, a Y combinator and VC backed company, raised an oversubscribed Seed Round to accelerate development and clinical studies. Awards & Accelerators: 1. Y Combinator 2. MassChallenge 3. Springboard Enterprises 4. MassMedic Ignite 5. Inc Magazine Top 100 Female Founders 6. Women's Health Innovation Summit Award 7. Massachusetts Life Sciences Center MassNextGen Award 8. The Wave Summit's Emerging Women Founder in Bio Award 9. The Eddies Award 10. Bloomberg New Economy Catalyst www.aoadx.com
- Website
-
http://www.aoadx.com
External link for AOA Dx
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Denver, CO
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Medical Devices, Diagnostics, Prognostics, Biotechnology, Sales, Commercialization, Regulatory, Licensing, Quality, FDA, IVD, CE IVDR, Ovarian Cancer, Women's Health, Cancer Diagnostics, and Liquid Biopsy
Locations
-
Primary
Denver, CO 80221, US
-
New York City, NY 10011, US
-
Cambridge, MA 02138, US
Employees at AOA Dx
-
Anthony Bajoras
Founder & Managing Director at CANCER FUND
-
Sharon Vosmek
CEO, Astia & Managing Partner, Astia Fund. Series A/B Investor, Board Member, Advisor, Speaker, fierce advocate for her portfolio
-
Alice Zheng
Principal at RH Capital | women's health expert | MD/MBA/MPH | ex-McKinsey
-
Abigail McElhinny
Experienced product development executive
Updates
-
We're less than 2 weeks away! AOA is thrilled to be part of the American Cancer Society's Fork Cancer event on July 18, 2024, at Mile High Station in Denver! Come enjoy Denver's finest culinary delights, drinks, and live entertainment with us, all while supporting a great cause. We're excited to participate this year because the American Cancer Society is focusing on increasing access and funding for biomarker testing in 2024. This is crucial for our test's market introduction and ensuring insurance covers its cost. Our GlycoLocate™ platform will be the first of its kind to use tumor marker gangliosides as biomarkers to diagnose early-stage cancers by using a non-invasive blood test. Join us in this important mission and help us reach our goal of $5,000! Learn more here: https://lnkd.in/dKGBVFSs
-
-
A recent study by the University of California, Berkeley has uncovered alarming findings. Widely used tampons contain toxic metals like arsenic and lead, potentially increasing health risks. Researchers tested 30 tampons from various brands and locations, finding all 16 tested metals in every product. "Toxic metals are particularly dangerous if they come into direct contact with the vagina, where they are more easily absorbed. Chronic metal absorption has been linked to increased risk of dementia, cancer, infertility, and other health issues."
Arsenic, Lead Among Toxic Metals in Tampons, Study Says
time.com
-
“The study reveals that women who experience early menopause (before age 40) have an increased risk of developing breast and ovarian cancer," she says. "These women face double the risk for breast cancer and nearly four times the risk for ovarian cancer compared to those who undergo menopause at a typical age. “Given these findings, for those women who undergo early menopause and those having fertility issues due to early menopause or low egg numbers, need to have regular cancer screenings, especially if there is a family history of cancer."
Early menopause linked to increased risk of breast and ovarian cancer
uk.style.yahoo.com
-
Congratulations to our CEO & Co-Founder Oriana Papin-Zoghbi for winning the People's Choice Award for the AIM-HI Accelerator Fund! We greatly appreciate everyone who took the time to cast their vote and show support for the work we are doing at AOA Dx!!
🎊 The 2024 Women’s Venture Competition launched the “People's Choice for Best Pitch” voting campaign, inviting the public audience to participate and vote for their favorite pitch from our seven semi-finalists. We are excited to announce that the “People's Choice for Best Pitch” goes to Oriana Papin-Zoghbi, CEO & Co-Founder of AOA Dx! Her compelling presentation introduced AOA’s groundbreaking novel technology for the early diagnosis of ovarian cancer, raising awareness about the importance of early cancer detection through the use of biomarkers. Congratulations to Oriana and the AOA team! Who will be the top finalists selected by the 2024 Women’s Venture Competition judging committee? Stay tuned to find out! https://lnkd.in/duHNVZQx #AIMHIaccelerator #WomensVentureCompetition #EmpoweringWomenInOncology #EmpoweringWomenEntrepreneurs #EarlyCancerDetection #OvarianCancer
-
-
Last week our Co-Founder & COO Alexander Fisher spoke at the Mountain West BioLife Summits in Denver to promote Colorado as a future hub of biotech! Moderator: Elyse Blazevich, President & CEO, Colorado BioScience Association, President, Colorado Bioscience Institute Panelists: Isaac Foster, CEO, Endourage Julie Stiff, Interim Site Head & Sr Director Facilities & Engineering, Boulder Operations, KBI Biopharma Erin Fosdick, President & CEO, Longmont Economic Development Partnership
-
-
We are excited to introduce you to Charles M. Nichols, Ph.D., our new Mass Spectrometry Scientist! Charles is a bioanalytical chemist that specializes in LCMS method development and validation. At AOA Dx, he works with developing assay platforms using HPLC-FC-ELSD and LC-HRMS/MS. Welcome Charles, we're thrilled to have you on board 👏 !
-
-
AOA is thrilled to be part of the American Cancer Society's Fork Cancer event on July 18, 2024, at Mile High Station in Denver! Come enjoy Denver's finest culinary delights, drinks, and live entertainment with us, all while supporting a great cause. We're excited to participate this year because the American Cancer Society is focusing on increasing access and funding for biomarker testing in 2024. This is crucial for our test's market introduction and ensuring insurance covers its cost. Our GlycoLocate™ platform will be the first of its kind to use tumor marker gangliosides as biomarkers to diagnose early-stage cancers by using a non-invasive blood test. Join us in this important mission and help us reach our goal of $5,000! Learn more here: https://lnkd.in/dKGBVFSs
-
-
"Early detection improves treatment outcomes for endometrial and ovarian cancers, yet far too often women are diagnosed in advanced stages of these diseases. Unlike many other cancers, there are no standard screenings for early detection of endometrial and ovarian cancers. The incidence rate for endometrial cancer is expected to rise, driven by environmental factors, obesity and diabetes."
Mayo Clinic researchers uncover microbial signatures linked to gynecologic cancers
news-medical.net
-
Warm welcome to our Chief of Staff Emma Martin!!! Emma is a mission-driven operator who is passionate about improving processes and culture within a leadership team and organization in order for everyone to work more effectively. She began her career as the fourth hire at a healthcare startup, where she played a pivotal role in establishing and developing the company's sales organization, and sold to Fortune 500 health plans. Her exceptional leadership and strategic acumen led to taking on the role as Chief of Staff, where she continued to drive organizational efficiency and support executive decision-making. Emma's unique blend of scientific knowledge and business expertise enables her to navigate the complexities of the healthcare industry effectively. Welcome Emma! We're so excited to have you on our team! 👏
-